Amundi Purchases 102,715 Shares of Organon & Co. $OGN

Key Points

• Amundi increased its holdings in Organon & Co. by 16.7% in Q1, owning a total of 719,105 shares valued at $10.39 million.
• Several other hedge funds significantly increased their stakes in Organon during the same quarter, reflecting growing interest among institutional investors.
• Organon recently announced a quarterly dividend of $0.02 per share, providing a 0.8% yield to investors.

Amundi increased its stake in Organon & Co. (NYSE:OGN - Free Report) by 16.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 719,105 shares of the company's stock after acquiring an additional 102,715 shares during the period. Amundi owned about 0.28% of Organon & Co. worth $10,392,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. NBC Securities Inc. lifted its stake in shares of Organon & Co. by 111,262.5% in the 1st quarter. NBC Securities Inc. now owns 8,909 shares of the company's stock valued at $132,000 after acquiring an additional 8,901 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in Organon & Co. by 42.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company's stock valued at $289,000 after purchasing an additional 5,758 shares during the period. M&T Bank Corp increased its holdings in Organon & Co. by 3.4% during the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company's stock valued at $833,000 after purchasing an additional 1,854 shares during the period. Cetera Investment Advisers increased its holdings in Organon & Co. by 62.7% during the 4th quarter. Cetera Investment Advisers now owns 76,005 shares of the company's stock valued at $1,134,000 after purchasing an additional 29,287 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Organon & Co. by 186.9% during the 1st quarter. GAMMA Investing LLC now owns 4,611 shares of the company's stock valued at $69,000 after purchasing an additional 3,004 shares during the period. Institutional investors own 77.43% of the company's stock.

Wall Street Analyst Weigh In

Separately, BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Organon & Co. currently has an average rating of "Moderate Buy" and an average price target of $17.33.

Organon & Co. Stock Down 2.5%

Shares of OGN traded down $0.27 during mid-day trading on Monday, reaching $10.39. The company had a trading volume of 3,892,533 shares, compared to its average volume of 3,483,656. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The firm has a 50-day moving average price of $9.65 and a 200 day moving average price of $10.79. Organon & Co. has a 52 week low of $8.01 and a 52 week high of $21.06. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 3.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.06. The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm's quarterly revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were given a $0.02 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 annualized dividend and a yield of 0.8%. Organon & Co.'s dividend payout ratio is 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.